VOOPOO
22.12.2021 11:17:05 CET | Business Wire | Press release
On December 15, 2021, Ecigclick, the well-known vape review site in the UK, announced the results of Ecigclick Vape Awards 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005114/en/
VOOPOO products won five awards including the Best Vape Brand 2021, becoming the benchmark brand winning the Best Vape Brand award for two consecutive years.
This outstanding annual achievement in awards, which covers different categories such as Mod, Pod Mod, Pod, Tank, once again verifies VOOPOO's excellent global brand influence. Its diversified product lineup has been recognized by the market and is well received by vapers worldwide.
The Ecigclick Vape Awards attracted more than 200 mainstream brands competing in various categories. More than 100,000 global vapers of mainstream communities from North America, the United Kingdom, and the European Union participated in the email voting.
This year, VOOPOO's four products (ARGUS, DRAG Nano 2, DRAG 3, TPP-X POD TANK) won the Best Vape Kit For Beginners, the Best POD, the Best MOD, and the Best Sub Ohm Tank respectively, thanks to VOOPOO's consumer-based insight and diversified product strategy.
It is with the changes in the market environment and technological innovation that vapers are getting more demanding. Scenario-based, lightweight and diversified products are becoming more and more popular in the market.
In view of this, VOOPOO invested in new product series based on vaper value, and launched a product lineup integrating DRAG, VINCI, ARGUS, and V series to provide vapers with more suitable product solutions and to continue to enhance vaper experience.
Every vaper can find his favorite way to experience, no matter what he likes — Mod, Pod Mod or Pod. VOOPOO respects the vapers' own choice and is pleased to diversify its offering.
VOOPOO will continue to develop its product ecosystem, allowing its DRAG, VINCI, ARGUS, and V series to integrate with each other, so that consumers can enjoy a safe, reliable, and diverse product ecosystem that can meet diversified needs.
About VOOPOO
Founded in 2017, VOOPOO has rapidly grown through DRAG products within a short period of time and is well recognized by vapers from around the world. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operations. It has four flagship product series: DRAG, VINCI, ARGUS and V Series. Its business covers more than 70 countries and regions in North America, Europe and Asia. For more information, please visit our website and follow our IG , Facebook and TikTok .
About Ecigclick
Ecigclick is one of the vape sites with the widest coverage and most active vapers in the world. Ecigclick Vape Awards, as its annual voting event, has been successfully held for 9 years. Its forward-looking ranking is well recognized and has a deep influence in the industry.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211219005114/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom